Previous 10 | Next 10 |
2024-01-25 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-16 23:01:41 ET Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. ...
2024-01-16 08:34:00 ET More on Solid Biosciences Solid Biosciences raises $109M through private placement Solid Biosciences receives FDA Fast Track designation for Duchenne gene therapy candidate Seeking Alpha’s Quant Rating on Solid Biosciences Histor...
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it ...
2024-01-12 08:14:44 ET More on Solid Biosciences Solid Biosciences raises $109M through private placement Solid Biosciences receives FDA Fast Track designation for Duchenne gene therapy candidate Seeking Alpha’s Quant Rating on Solid Biosciences Histor...
2024-01-09 12:43:25 ET Gainers: Neximmune NEXI +96% . Sentage Holdings SNTG +58% . Mountain Crest Acquisition Corp IV MCAF +48% . Zoomcar Holdings ZCAR +42% . Cutera CUTR +37% . Adicet Bio ( ACET ) +33% . Solid Biosciences ( SLDB ...
2024-01-08 11:36:08 ET DENVER, Colo., Jan. 8, 2023 ( www.247marketnews.com )- Solid Biosciences Inc. (NASDAQ: SLDB) stated, this morning, that it entered into a securities purchase agreement with a select group of institutional accredited investors to sell 16,973,103 shares of common st...
2024-01-08 07:30:07 ET Solid Biosciences ( NASDAQ: SLDB ) has entered into private placement to sell 16,973,103 shares of common stock at a price of $5.53 per share and, in lieu of common stock, pre-funded warrants to purchase up to 2,712,478 shares of common stock at a price...
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of insti...
CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
2024-07-06 13:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...